Castration-resistant Prostate Cancer Clinical Trial
Official title:
Xtandi® Capsules 40 mg Protocol for Long-Term Specified Drug Use-Results Survey
The purpose of this study is to confirm the long term safety and efficacy of enzalutamide in patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00974311 -
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
|
Phase 3 | |
| Active, not recruiting |
NCT03700099 -
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
|
Phase 2 | |
| Completed |
NCT02124668 -
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
|
Phase 2 | |
| Completed |
NCT01634061 -
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
|
Phase 1 | |
| Completed |
NCT01338831 -
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
|
Phase 1 | |
| Terminated |
NCT03652493 -
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
|
Phase 2 | |
| Recruiting |
NCT04549207 -
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
|
Phase 4 | |
| Active, not recruiting |
NCT03305224 -
The Combination Therapy With Ra-223 and Enzalutamide
|
Phase 2 | |
| Active, not recruiting |
NCT04090528 -
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT04070209 -
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
|
Phase 2 | |
| Active, not recruiting |
NCT06193993 -
Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients
|
Phase 1 | |
| Active, not recruiting |
NCT05084859 -
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03934164 -
Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO
|
||
| Recruiting |
NCT03506997 -
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT03569280 -
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
|
Phase 1 | |
| Enrolling by invitation |
NCT03356912 -
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy
|
Phase 2 | |
| Not yet recruiting |
NCT04148885 -
A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03356444 -
Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate
|
Phase 2 |